The preliminary indication of antitumor activity in BRAF-mutated melanoma is promising although further clinical development of single agent use in this setting in tumors that do not harbor RAF fusions (e.g., those with KRAS or NRAS mutations) is likely to be limited. This evidence concerns the gene BRAF and melanoma.